- Home
- SILC vs GALT Comparison
SILC vs GALT Comparison
Compare SILC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | GALT |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.8M | 199.2M |
| IPO Year | 2002 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SILC | GALT |
|---|---|---|
| Price | $42.95 | $2.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 111.5K | ★ 273.9K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $1.22 |
| 52 Week High | $48.92 | $7.13 |
Technical Indicators
Market Signals| Indicator | SILC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 73.79 | 47.27 |
| Support Level | $16.10 | $2.18 |
| Resistance Level | N/A | $2.60 |
| Average True Range (ATR) | 3.72 | 0.14 |
| MACD | 0.96 | 0.01 |
| Stochastic Oscillator | 75.31 | 60.01 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.